Skip to main content
HairCited

Spironolacton für Androgenetische Alopezie

A

Basierend auf 25 Studien (4 meta-analyses, 2 RCTs) mit 6,273 Teilnehmern insgesamt. 19/25 Studien zeigen positive Effekte.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'haircited.com'; const params = 'ingredient\u003Dspironolactone\u0026condition\u003Dandrogenetic\u002Dalopecia'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    

Widget powered by . Free, no account required.

A

Fazit

Spironolactone is well-supported by research as an anti-androgen medication that may help reduce hair loss in androgenetic alopecia, particularly in women, though it requires medical supervision.

  • 76% of studies show positive effects, backed by 4 meta-analyses
  • Works by blocking androgen hormones that contribute to hair miniaturization
  • Particularly studied in women with PCOS-related and female pattern hair loss
  • Requires prescription and medical monitoring due to hormonal effects

Key Study Findings

Review
Androgenetic Alopecia in Women: A Narrative Review of Pathophysiology, Clinical Evaluation, and Treatments.
Dose: None vs.: None Outcome: None Wirkung: None None

Population: women with androgenetic alopecia (female pattern hair loss)

Review
Male and female pattern hair loss.
Dose: None vs.: Placebo Wirkung: None None
RCT n=48 24 weeks Double-blind
Efficacy and safety of oral spironolactone for female pattern hair loss in premenopausal women: a …
Dose: Spironolactone 100 mg once daily vs.: Placebo Wirkung: Terminal hair counts: 9.48 vs 5.32 hairs/cm2; hair diameter: 4.23 vs 2.96 μm; moderate-to-marked imp p=0.063 (terminal hair counts)
Randomized Controlled Trial n=125 4 weeks Double-blind
Effects of a cannabidiol/terpene formulation on sleep in individuals with insomnia: a double-blind, placebo-controlled, randomized, …
Dose: CBD 300 mg + 1 mg each of 8 terpenes vs.: Placebo Outcome: Percentage of time in SWS + REM sleep Wirkung: 1.3% increase [0.1-2.5%]; up to 48 min/night in su 0.03

Population: Individuals with insomnia

Cohort Study n=203
An international multicenter, retrospective cohort study of 203 patients with pediatric androgenetic alopecia.
Dose: None vs.: None Outcome: Clinical presentation and treatment outcomes in pediatric AGA Wirkung: None None

Population: Pediatric patients with androgenetic alopecia (multicenter)

Randomized Controlled Trial n=30
A Prospective and Comparative Study to Explore the Effects of Platelet-Rich Plasma in Hair Transplantation …
Dose: None vs.: Drug therapy (minoxidil + finasteride/spironolactone) only Outcome: Follicle survival rate, growth rate, hair strength Wirkung: None None

Population: Patients with androgenetic alopecia

Key Statistics

45

Studien

6472

Teilnehmer

Positive

A

Bewertung

Referenced Papers

Australian prescriber 2025 2 Zitierungen
Journal of cosmetic … 2024 11 Zitierungen
JAAD international 2023 80 Zitierungen
Clinical, cosmetic and … 2023 58 Zitierungen
Alternative therapies in … 2020 11 Zitierungen
Journal of the … 2019 55 Zitierungen
International journal of … 2018 129 Zitierungen
BMJ case reports 2017 6 Zitierungen
The Cochrane database … 2016 18 Zitierungen
The Medical clinics … 2015 66 Zitierungen
Journal of the … 2015 50 Zitierungen
Current problems in … 2015 8 Zitierungen
International journal of … 2013
Seminars in cutaneous … 2009 4 Zitierungen
The Australasian journal … 2007 32 Zitierungen
Revue medicale de … 2004
Current pharmaceutical design 1999
Journal of the … 1999
Dermatologic clinics 1998 121 Zitierungen

Dosage & Usage

mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units

Übliche Dosierungen

hairloss:
100-200 mg/day (prescription)

Obergrenze: 200 mg/day (hair loss indication)

In der Forschung untersuchte Dosierungen

Dosierung Dauer Wirkung N
None -- Neutral --
None -- Positive --
Spironolactone 100 mg once daily 24 weeks Positive 48
CBD 300 mg + 1 mg each of 8 terpenes 4 weeks Positive 125
None -- Positive 203
None -- Positive 30
various across included studies (2015-2024) -- Positive --
None -- Mixed --

Beste Einnahmezeit: Once or twice daily with food; prescription required

Safety & Side Effects

Gemeldete Nebenwirkungen

  • Menstrual irregularities
  • Breast tenderness
  • Hyperkalemia (elevated potassium levels)
  • Dizziness and orthostatic hypotension
  • Frequent urination

Bekannte Wechselwirkungen

  • ACE inhibitors and ARBs (increased hyperkalemia risk)
  • Potassium supplements and potassium-sparing diuretics (dangerous hyperkalemia)
  • NSAIDs (may reduce diuretic effectiveness and increase kidney risk)
  • Digoxin (spironolactone may increase digoxin levels)

Tolerierbare Höchstaufnahmemenge: 200 mg/day (hair loss indication)

Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.

Frequently Asked Questions

Does Spironolacton help with Androgenetische Alopezie?
Based on 45 studies with 6,472 participants, there is strong evidence from multiple clinical trials that Spironolacton may support Androgenetische Alopezie management. Our evidence grade is A (Strong Evidence).
How much Spironolacton should I take for Androgenetische Alopezie?
Studies have used various dosages. A commonly studied range is 100-200 mg/day (prescription). Always consult your healthcare provider before starting any supplement regimen.
Are there side effects of Spironolacton?
Reported side effects may include Menstrual irregularities, Breast tenderness, Hyperkalemia (elevated potassium levels), Dizziness and orthostatic hypotension. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
How strong is the evidence for Spironolacton and Androgenetische Alopezie?
We rate the evidence as Grade A (Strong Evidence). This rating is based on 45 peer-reviewed studies with 6,472 total participants. The overall direction of effect is positive.

Related Evidence

Spironolacton für andere Beschwerden

FDA-Haftungsausschluss: Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.